BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Period	Debt/Equity
2015-12-31	1.56
2016-12-31	55.94
2017-12-31	1.13
2018-12-31	1.98
2019-12-31	3.58
2020-12-31	-18.38
2021-12-31	-6.50
2022-12-31	-2.87
2023-12-31	-2.13
2024-12-31	-2.03

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BCRX	$8.94	+2.05%	2.62M
3
4
5

BioCryst Pharmaceuticals Inc. (BCRX) Debt to Equity Ratio

Debt to Equity Ratio Data

Get BioCryst Pharmaceuticals Inc. Data in Excel

More BCRX Financial Data